Redmile Group LLC Boosts Stock Position in Silence Therapeutics plc (NASDAQ:SLN)

Redmile Group LLC raised its holdings in shares of Silence Therapeutics plc (NASDAQ:SLN) by 26.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,399,317 shares of the company’s stock after purchasing an additional 500,000 shares during the quarter. Silence Therapeutics accounts for approximately 1.2% of Redmile Group LLC’s investment portfolio, making the stock its 25th largest holding. Redmile Group LLC owned approximately 8.02% of Silence Therapeutics worth $16,507,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in SLN. JPMorgan Chase & Co. bought a new position in shares of Silence Therapeutics during the fourth quarter valued at approximately $26,000. Barclays PLC increased its holdings in shares of Silence Therapeutics by 83.8% in the 4th quarter. Barclays PLC now owns 6,126 shares of the company’s stock valued at $42,000 after acquiring an additional 2,793 shares during the period. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Silence Therapeutics during the 4th quarter worth $69,000. Virtus ETF Advisers LLC boosted its position in Silence Therapeutics by 130.5% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,772 shares of the company’s stock valued at $74,000 after purchasing an additional 6,098 shares in the last quarter. Finally, Ameriprise Financial Inc. bought a new stake in Silence Therapeutics during the fourth quarter valued at about $113,000. 98.73% of the stock is currently owned by institutional investors.

Silence Therapeutics Stock Down 1.2%

NASDAQ:SLN opened at $4.06 on Thursday. Silence Therapeutics plc has a 52 week low of $1.97 and a 52 week high of $24.38. The stock’s 50-day moving average price is $3.34 and its 200-day moving average price is $6.28. The stock has a market capitalization of $121.52 million, a PE ratio of -2.59 and a beta of 1.20.

Silence Therapeutics (NASDAQ:SLN) last posted its quarterly earnings data on Thursday, May 8th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.42). Silence Therapeutics had a negative net margin of 342.00% and a negative return on equity of 62.81%. The business had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $3.58 million. Sell-side analysts expect that Silence Therapeutics plc will post -1.77 earnings per share for the current fiscal year.

Analyst Ratings Changes

SLN has been the subject of several analyst reports. Morgan Stanley decreased their price target on shares of Silence Therapeutics from $45.00 to $25.00 and set an “overweight” rating for the company in a research report on Friday, May 9th. The Goldman Sachs Group lowered their target price on shares of Silence Therapeutics from $4.00 to $3.00 and set a “sell” rating for the company in a research note on Friday, May 9th. Chardan Capital dropped their target price on Silence Therapeutics from $55.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price target on shares of Silence Therapeutics in a report on Friday, March 7th. Finally, BMO Capital Markets decreased their target price on Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Silence Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $33.83.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.